On the back of positive data presented at the recently concluded ASH meeting, Kite filed for approval of KTE-X19 in mantle cell lymphoma. The company currently markets another CAR-T, Yescarta, for a different form of lymphoma.
More than years after its initial approval, Kymriah has shown comparable efficacy and an apparently better safety profile than it demonstrated in the studies that led to its leukemia and lymphoma approvals. Another therapy, made by BMS, is a potential competitor.
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
The company is developing the drug, MGTA-145 as a one-day stem cell-mobilization product, compared with current standard G-CSF, which must be administered over several days and is associated with severe side effects.
In data from several clinical trials released Friday and during the weekend, cell and other therapies for multiple myeloma targeting the antigen BCMA showed strong response rates.
ArQule's lead product candidate is a BTK inhibitor, ARQ-531, designed for heavily pretreated patients with leukemias and lymphomas, particularly those whose disease has become resistant to marketed BTK therapies. Phase I data on the drug were also presented Monday.
Data showed LOXO-305 was broadly effective in patients resistant to BTK inhibitors regardless of whether they harbored a putative mechanism of resistance to the widely used blood cancer drugs.
When it comes to managing inbound phone calls, underperformance has devastating cost implications.